Interest Income
For the three months ended September 30, 2023 and 2022, the Company generated interest income of $130 and $78, respectively, and $391 and $100 for the nine months ended September 30, 2023 and 2022, respectively, from investments of the remaining proceeds from its December 2021 rights offering. These increases from period-to-period were primarily the result of the substantially higher short-term interest rates that existed during 2023, partially offset by the lower average cash balances available for investment during the three- and nine- month periods ended September 30, 2023.
Accretion expense
We recorded accretion expense of $70 and $71 for the three months ended September 30, 2023 and 2022 and $212 and $213 for the nine months ended September 30, 2023 and 2022, in each case related to the Company’s option to repurchase approximately 640 acres of non-core real property in Wyoming for not less than $1,200 nor greater than $1,850 in the form of cash, or a combination of cash and common shares of the Company. Accretion expense is recorded each reporting period to increase the repurchase option liability to the maximum exercise price of $1,850, less any annual option payments of $25. See Note 7 to the Consolidated Financial Statements for a discussion of the repurchase option.
Financial Position, Liquidity and Capital Resources
Operating Activities
Net cash used in operating activities increased by $2,624, rising to $8,766 for the nine months ended September 30, 2023 from $6,142 for the nine months ended September 30, 2022. This change was largely attributable to the $2,800 increase in cash advances paid under the Cost Share Agreement during the nine-month period ended September 30, 2023 as compared to the nine-month period ended September 30, 2022.
Investing Activities
Net cash used in investing activities of $4 for the nine months ended September 30, 2023 resulted from a $12 sale of non-essential equipment, offset by a $16 purchase of equipment. There were no similar transactions during the nine months ended September 30, 2022.
Financing Activities
Net cash provided by financing activities of $23 for the nine months ended September 30, 2023 stemmed from the exercise of 330,000 stock options. There were no similar transactions during the nine months ended September 30, 2022.
Financial Position, Liquidity and Capital Resources
At September 30, 2023, we had a working capital balance of $10,118 which represented a decrease of $7,510 from our December 31, 2022 working capital balance of $17,628. This decrease was largely the result of amounts paid by the Company during the nine months ended September 30, 2023 under the Cost Share Agreement and for the payment of other ongoing expenses.
In June 2023, the Company entered into the Funding Agreement for its previously announced award of a $4,400 grant from the WEA to be used toward the advancement of the Demonstration Plant. The WEA grant is a cost-reimbursement award that will be available to the Company for the reimbursement of future Demonstration Plant expenses. As of September 30, 2023, no amount of the $4,400 award had been received by the Company and no amounts related to this grant have been included in the Company’s September 30, 2023 financial statements. The Company may be able to claim a portion of the $4,400 grant during the fourth quarter of 2023 as discussed in Note 7.
Inclusive of amounts already advanced of $13,700 through September 30, 2023, the Company’s share of the total costs under the Cost Share Agreement are expected to exceed $22,000 over the life of the Demonstration Plant project. As a result, the project team has commenced discussions with the DoE and other government agencies regarding further cost-sharing opportunities to offset the increase in the anticipated project budget and further project objectives. At this time, the Company has sufficient funding to complete construction